

US EPA ARCHIVE DOCUMENT

# DATA EVALUATION RECORD

CHLOROTHALONIL

Study Type: §84-2; Bacterial Reverse Gene Mutation Assay

Work Assignment No. 2-01-35 I; formerly 1-01-35 I (MRID 45710213)

Prepared for

Health Effects Division  
Office of Pesticide Programs  
U.S. Environmental Protection Agency  
1921 Jefferson Davis Highway  
Arlington, VA 22202

Prepared by

Pesticide Health Effects Group  
Sciences Division  
Dynamac Corporation  
1910 Sedwick Road, Bldg. 100, Ste. B.  
Durham, NC 27713

Primary Reviewer:  
David McEwen, B.S.

*Mary Menetrez for*  
Signature: David McEwen  
Date: 9/8/04

Secondary Reviewer:  
Ronnie J. Bever Jr., Ph.D.

Signature: Ronnie J. Bever Jr.  
Date: 9/8/04

Program Manager:  
Mary L. Menetrez, Ph.D.

Signature: Mary L. Menetrez  
Date: 9/10/04

Quality Assurance:  
Steven Brecher, Ph. D

Signature: Steven Brecher  
Date: 9/10/04

### Disclaimer

This Data Evaluation Record may have been altered by the Health Effects Division subsequent to signing by Dynamac Corporation personnel.

CHLOROTHALONIL/PC code: 081901

OPPTS 870.5100/ OECD 471

EPA Reviewer: Lisa AustinSignature: [Signature]

Registration Action Branch 1, Health Effects Division (7509C)

Date

9/13/05EPA Secondary Reviewer: William Greear, M.P.H., D.A.B.Signature: [Signature]

[Insert Branch], Health Effects Division (7509C)

Date

9/9/2005Work Assignment Manager: P.V. Shah, Ph.D.Signature: [Signature]

Registration Action Branch 1, Health Effects Division (7509C)

Date

12/15/05

Template version 11/01

<b>DATA EVALUATION RECORD</b>
-------------------------------

**STUDY TYPE:** *In vitro* Bacterial Gene Mutation (*Salmonella typhimurium*)/ mammalian activation gene mutation assay; OPPTS 870.5100 [§84-2]; OECD 471 (formerly OECD 471 & 472).

**PC CODE:** 081901**DP BARCODE:** 301496**TXR#:** 0052493**SUBMISSION NO.:** None**TEST MATERIAL (PURITY):** Chlorothalonil technical (98.74% a.i., Batch # 46/87)**SYNONYMS:** 2,4,5,6 Tetrachloro-1,3-benzenedicarbonitrile

**CITATION:** Forster, R. (1988) Reverse mutation in *Salmonella typhimurium*. Life Science Research, Rome Toxicology Centre S.p.A., Pomezia (Rome), Italy. Laboratory Report No.: LSR-RTC 128006-M-10587, May 6, 1988. MRID 45710213. Unpublished.

**SPONSOR:** Vischim S.R.L., Via Friuli, 55, Cesano Maderno (Milan), Italy

**EXECUTIVE SUMMARY** - In two independent reverse gene mutation assays in bacteria (MRID 45710213), *Salmonella typhimurium* strains TA98, TA100, TA1535, TA1537, and TA1538 were exposed to Chlorothalonil technical (98.74% a.i., Batch # 46/87) in dimethylsulfoxide at concentrations of 0, 3.13, 6.25, 12.5, 25, or 50 µg/plate in the presence of mammalian metabolic activation (+S9) and 0, 1.56, 3.13, 6.25, 12.5, or 25 µg/plate in the absence of metabolic activation (-S9). The standard plate incorporation method was performed (+/-S9). Standard strain-specific mutagens served as positive controls.

Chlorothalonil technical was tested up to cytotoxic concentrations. In the presence of mammalian metabolic activation, cytotoxicity (as indicated by reduction in number of revertants or thinning of the background lawn) was observed at  $\geq 25$  µg/plate (TA1537) and at 50 µg/plate (TA98, TA100, TA1535, and TA1538). In the absence of mammalian metabolic activation, cytotoxicity was observed at  $\geq 12.5$  µg/plate (TA100, TA1535 and TA1537) and at 25 µg/plate (TA98 and TA1538). No marked increases in the number of revertants were observed at any concentration in any strain in either trial. The positive controls induced marked increases in

CHLOROTHALONIL/PC code: 081901

OPPTS 870.5100/ OECD 471

revertant colonies compared to controls in both trials. **There was no evidence of induced mutant colonies over background.**


The study is classified as **acceptable/guideline** and satisfies the guideline requirements (OPPTS 870.5100; OECD 471) for *in vitro* mutagenicity (bacterial reverse gene mutation) data.

**COMPLIANCE** - Signed and dated GLP, Quality Assurance, and Data Confidentiality statements were provided.

**I. MATERIALS AND METHODS**

**A. MATERIALS**

- 1. Test material:** Chlorothalonil technical  
**Description:** White microcrystalline powder  
**Batch #:** 46/87  
**Purity (w/w):** 98.74% a.i.  
**CAS # of TGAI:** 1897-45-6  
**Structure:**



**Solvent used:** Dimethylsulfoxide (DMSO)

**2. Control materials**

**Negative** - The solvent alone and untreated cultures served as negative controls.

**Solvent** - DMSO (0.1 mL/plate)

**Positive**

Non-activation

- |                                   |             |               |
|-----------------------------------|-------------|---------------|
| Sodium azide (in distilled water) | 1 µg/plate  | TA100, TA1535 |
| 2-Nitrofluorene (in DMSO)         | 2 µg/plate  | TA98, TA1538  |
| 9-Aminoacridine (in DMSO)         | 50 µg/plate | TA1537        |

Activation

- |                             |            |                                     |
|-----------------------------|------------|-------------------------------------|
| 2-Aminoanthracene (in DMSO) | 1 µg/plate | TA98, TA100, TA1535, TA1537, TA1538 |
|-----------------------------|------------|-------------------------------------|

**3. Activation** - The S9 fraction was derived from young male Sprague-Dawley rats (Charles River, Como, Italy) weighing approximately 200-250 g:

X	induced		Aroclor 1254	X	Rat	X	Liver
	non-induced	X	Phenobarbital		Mouse		Lung
		X	β-naphthoflavone		Hamster		Other
			Other		Other		

The S9 fraction was prepared in the study laboratory and stored at -80°C prior to use. Each batch was checked for protein content; aminopyrene demethylase activity, sterility, and efficacy. The S9 fraction was mixed with the following cofactors to make the S9 mix: glucose-6-phosphate (100 mM), NADP (100 mM), MgCl<sub>2</sub> (100 mM), KCl (330 mM), phosphate buffer (200 mM) at pH 7.4, and distilled water. The final S9 culture concentration was approximately 1.9%.

**4. Test organisms** - *S. typhimurium* and *E. coli* strains

	TA97	X	TA98	X	TA100		TA102		TA104
X	TA1535	X	TA1537	X	TA1538		WP2 <i>hvrA</i>		WP2 (pKM101)

Properly maintained?

Yes

No

Checked for appropriate genetic markers (*rfa* mutation, R factor)?

Yes

No

162

**5. Test compound concentrations used****Preliminary cytotoxicity assay - All strains**

Non-activated conditions: 25, 79, 250, 790, or 2500 µg/plate (Trial 1); 0.250, 0.791, 2.5, 7.9, or 25 µg/plate (Trial 2)

Activated conditions: 25, 79, 250, 790, or 2500 µg/plate (Trial 1); 0.250, 0.791, 2.5, 7.9, or 25 µg/plate (Trial 2)

**Mutagenicity assay - All strains**

Non-activated conditions: 0, 1.56, 3.13, 6.25, 12.5, or 25 µg/plate (Trials 1 and 2)

Activated conditions: 0, 3.13, 6.25, 12.5, 25, or 50 µg/plate (Trials 1 and 2)

All concentrations of the test article and positive controls were plated in triplicate, both in the presence and absence of S9-activation, for each tester strain (*S. typhimurium* TA98, TA100, TA1535, TA1537, and TA1538). Solvent and untreated controls were plated in triplicate both in the presence and absence of S9.

**B. TEST PERFORMANCE****1. Type of assay**

- standard plate test
- pre-incubation (\_\_\_ minutes)
- "Prival" modification (*i.e. azo-reduction method*)
- spot test
- other

**2. Protocol** - Two independent mutagenicity trials, each using the standard plate incorporation method were conducted both in the presence and absence of S9. Prior to plating, inocula of the tester strains were cultured in nutrient broth overnight at 37°C. Bacteria (0.1 mL); test compound, solvent, or positive control (0.1 mL); and 0.5 mL of S9 mix (for tests requiring metabolic activation) or phosphate buffer were added to 2 mL of melted top agar supplemented with histidine-biotin solution. The top agar components were thoroughly mixed and poured into triplicate plates containing solidified minimal agar. After solidification, the plates were inverted and incubated for approximately 72 hours at 37°C. After incubation, the plates were scored (or held at 4°C prior to scoring) for number of revertant colonies using an automatic counting system (Artek Model 890).

**3. Statistical analysis** - A regression analysis of the data was performed.

**4. Evaluation criteria**

**Assay validity** - The assay validity criteria were not provided; however, typically the following criteria indicate a valid experiment:

- The negative control plates showed regular background growth.
- The spontaneous reversion rates in the negative controls were within the historical control range.

CHLOROTHALONIL/PC code: 081901

- The positive controls induced clear increases in revertant colonies compared to solvent controls.

**Positive result** - The test article was considered to be mutagenic if the following criteria were met:

- The mean number of revertants was more than 2x the solvent control rate in any strain at two consecutive concentrations or at the last non-toxic concentration.
- A concentration-related increase in the number of revertants was observed.
- The results were reproducible.

## II. REPORTED RESULTS

The test substance was soluble in DMSO at 25 mg/mL. Therefore, 2500 µg/plate was selected as the maximum concentration for the preliminary toxicity test. Dose formulations were not analyzed for actual concentrations.

**A. PRELIMINARY CYTOTOXICITY ASSAY** - Precipitation was observed at  $\geq 790$  µg/plate ( $\pm S9$ ). In two trials (-S9), toxicity was observed at concentrations  $\geq 25$  µg/plate in all strains and  $\geq 2.5$  µg/plate in TA1537. In two trials (+S9), toxicity was observed at concentrations  $\geq 79$  µg/plate in strains TA98, TA100, and TA1535,  $\geq 25$  µg/plate in TA1537 (one trial), and  $\geq 250$  µg/plate in TA1538. Therefore, 25 µg/plate (-S9) and 50 µg/plate (+S9) were selected as the highest concentrations for the mutagenicity assays.

**B. MUTAGENICITY ASSAY** - The results of the mutagenicity trials were tabulated for each strain, Tables 3-12 on Study Report pages 18-27. The results of these assays were negative; therefore, copies of Table 4 (Trial 1) and Table 9 (Trial 2) for strain TA1537 are included as representative examples in the Attachment to this DER. In both trials, tester strains TA98, TA100, TA1535, TA1537, and TA1538 were exposed to the test article at concentrations of 0, 1.56, 3.13, 6.25, 12.5, or 25 µg/plate (-S9) and 0, 3.13, 6.25, 12.5, 25, or 50 µg/plate (+S9). Cytotoxicity (as indicated by reduction in number of revertants or thinning of the background lawn) was observed (-S9) at  $\geq 12.5$  µg/plate (TA100, TA1535 and TA1537) and at 25 µg/plate (TA98 and TA1538). Cytotoxicity was observed (+S9) at  $\geq 25$  µg/plate (TA1537) and at 50 µg/plate (TA98, TA100, TA1535, and TA1538). No marked increases in the number of revertants were observed at any concentration in any strain in either trial. The positive controls induced marked increases in revertant colonies compared to controls in both trials.

## III. DISCUSSION and CONCLUSIONS

**A. INVESTIGATORS' CONCLUSIONS** - The investigator concluded that under the conditions of this study, Chlorothalonil technical did not induce mutations in *S. typhimurium* strains TA98, TA100, TA1535, TA1537 or TA1538 when tested up to a toxic dose level in the presence or absence of S9-activation.

**B. REVIEWER COMMENTS** - Chlorothalonil technical was tested up to cytotoxic concentrations (12.5-25 µg/mL, -S9) and (25-50 µg/mL,+S9). No precipitation was observed in either trial. No marked increases in the number of revertants were observed at any concentration in any strain in either trial. The positive controls induced marked increases in revertant colonies compared to controls in both trials. **There was no evidence of induced mutant colonies over background.** It should be noted that the study was conducted in 1988, when *S. typhimurium* strain TA1538 was commonly used instead of strain TA102 or *Escherichia coli* strain WP2.

The study is classified as **acceptable/guideline** and satisfies the guideline requirements (OPPTS 870.5100; OECD 471) for *in vitro* mutagenicity (bacterial reverse gene mutation) data.

**C. STUDY DEFICIENCIES** - The following minor deficiency was noted, but does not change the conclusions of this DER:

- The dose formulations were not analyzed for actual concentrations.
- The evaluation criteria for assay validity were not provided.



US EPA ARCHIVE DOCUMENT

ATTACHMENT

164

CHLOROTHALONIL/PC code: 081901

OPPTS 870.5100/ OECD 471

LSR-RTC Department of Genetic Toxicology  
Reverse Mutation in S. typhimurium

Test Substance : CHLOROTHALONIL TECHNICAL  
Strain : TA 1537 Titre : 2.00  
Experiment No. : 1 Solvent: DMSO  
Experiment date: 21-Jan-88 S9: B7/28

Dose-level [ug/pl]	Without metabolic activation					With metabolic activation				
	Plate counts			Mean	S.E.	Plate counts			Mean	S.E.
Untreated	23	18	30	24	3.5	30	27	35	31	2.3
0.00	16	26	23	22	3.0	24	24	30	26	2.0
1.56	26	22	19	22	2.0	-	-	-	-	-
3.13	19	17	22	19	1.5	27	27	31	28	1.3
6.25	26	19	26	24	2.3	28	25	30	28	1.5
12.5	15TT	20TT	25TT	20	2.9	19	29	24	24	2.9
25.0	MTT	MTT	MTT	-	-	26T	26T	25T	26	0.3
50.0	-	-	-	-	-	23T	27T	26T	25	1.2

Regression analysis:

Points	S9	Intercept	Slope	Corr. coeff.	t	P-value
1 - 3	-	4.699	-0.0762	-0.25865	0.7084	0.50158
1 - 4	-	4.571	0.0279	0.16788	0.5385	0.60200
1 - 5	-	4.654	-0.0098	-0.10527	0.3817	0.70886
1 - 3	+	5.142	0.0259	0.27839	0.7669	0.46822
1 - 4	+	5.258	-0.0220	-0.30926	1.0284	0.32800
1 - 5	+	5.195	-0.0077	-0.22859	0.8466	0.41253
1 - 6	+	5.164	-0.0035	-0.21145	0.8654	0.39963

Positive and negative controls

Treatment	S9	Plate counts	Mean	S.E.
DMSO	100 u1/pl	- 16 26 23	22	3.0
9-Aminoacridine	50 ug/pl	- 151 113 357	207	75.8
DMSO	100 u1/pl	+ 24 24 30	26	2.0
2-Aminoanthracene	1 ug/pl	+ 132 104 C	118	14.0

ARTEK calibration factors: A = 0.5716 B = 1.1220

LSR-RTC Department of Genetic Toxicology  
Reverse Mutation in S. typhimurium

Test Substance : CHLOROTHALONIL TECHNICAL  
Strain : TA 1537 Titre : 2.11  
Experiment No. : 2 Solvent: DMSO  
Experiment date: 8 APRIL 88 S9: 88/2

Dose-level [ug/pl]	Without metabolic activation					With metabolic activation				
	Plate counts			Mean	S.E.	Plate counts			Mean	S.E.
Untreated	13	22	18	18	2.6	23	28	18	23	2.9
0.00	12	10	27	16	5.4	20	29	31	27	3.4
1.56	25	18	20	21	2.1	-	-	-	-	-
3.13	13	15	10	13	1.5	26	19	15	20	3.2
6.25	26	25	14	22	3.8	26	24	24	25	0.7
12.5	17TT	16TT	16TT	16	0.3	23	18	28	23	2.9
25.0	MTT	MTT	MTT			18	26	22	22	2.3
50.0	-	-	-	-	-	7T	12T	10T	10	1.5

Regression analysis:

Points	S9	Intercept	Slope	Corr. coeff.	t	P-value
1 - 3	-	4.210	-0.1213	-0.21540	0.5836	0.57780
1 - 4	-	3.974	0.0706	0.22268	0.7223	0.48665
1 - 5	-	4.117	0.0055	0.03646	0.1315	0.89736
1 - 3	+	4.935	-0.0269	-0.13787	0.3683	0.72354
1 - 4	+	4.899	-0.0123	-0.11697	0.3724	0.71733
1 - 5	+	4.884	-0.0089	-0.16832	0.6157	0.54873
1 - 6	+	5.077	-0.0348	-0.76569	4.7617	0.00021

Positive and negative controls

Treatment	S9	Plate counts	Mean	S.E.
DMSO 100 ul/pl	-	12 10 27	16	5.4
9-Aminoacridine 50 ug/pl	-	106 126 189	140	25.0
DMSO 100 ul/pl	+	20 29 31	27	3.4
2-Aminoanthracene 1 ug/pl	+	135 135 103	124	10.7

ARTEK calibration factors: A = 0.5716 B = 1.1220

168